SCM
EDIT icon

Silvant Capital Management’s Editas Medicine EDIT Stock Holding History

Silvant Capital Management’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,858
Closed -$76K – 336
2021
Q4 		$76K Sell
2,858
-183
-6% -$6.3K 0.01% 248
2021
Q3 		$125K Hold
3,041
– – 0.02% 212
2021
Q2 		$172K Hold
3,041
– – 0.03% 195
2021
Q1 		$128K Buy
+3,041
New +$173K 0.02% 215

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Silvant Capital Management's EDIT Position: Q1 2022 in Review

Silvant Capital Management sold out of Editas Medicine (EDIT) in Q1 2022, closing a stake of 2,858 shares — an estimated $76K sold.

Silvant Capital Management first reported a position in EDIT in Q1 2021 and held it in 4 quarters. The position peaked at $172K in Q2 2021. 256 funds tracked by Wall St. Rank hold EDIT as of Q1 2022.

  • Silvant Capital Management reported no remaining Editas Medicine position as of Q1 2022 after selling out during the quarter.
  • Silvant Capital Management sold 2,858 Editas Medicine shares in Q1 2022, an estimated $76K.
  • Silvant Capital Management first reported a position in Editas Medicine in Q1 2021 and held it in 4 quarters.
  • Silvant Capital Management's Editas Medicine position peaked at $172K in Q2 2021.
  • 256 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2022.

Based on Silvant Capital Management's 13F filing for Q1 2022, filed 5 May 2022.